Tracy I. George, MD

Medical Director: Hematopathology
Professor (Clinical), University of Utah School of Medicine

Specialties

• Hematopathology
• Laboratory hematology

Education

• Medical Degree—University of California, San Francisco School of Medicine
• Residency—Pathology and Laboratory Medicine, University of California, San Francisco School of Medicine
• Fellowship—Hematopathology, Stanford University School of Medicine
• Fellowship—Surgical Pathology, Stanford University School of Medicine

Current/Past Roles

• Chief Medical Officer, ARUP Laboratories
• Executive Director, Clinical Trials and PharmaDx, ARUP Laboratories
• Vice Chair of Clinical Affairs, University of New Mexico Department of Pathology
• Past President of the International Society for Laboratory Hematology
• Secretary/Treasurer of the American Initiative in Mast Cell Diseases (AIM)

Certification/Affiliations

• American Board of Pathology (Anatomic and Clinical Pathology, Hematology)

Research Interests

• Mast cell disease
• Translational hematopathology
• Laboratory hematology

Awards

• Healthcare Hero, Utah Business Magazine
• Lifetime Achievement Award, College of American Pathologists
• First Annual Dr. Steve Chen Hematopathology Lectureship, University of New Mexico

Recent Publications

• Al-Ghamdi YA, Lake J, Bagg A, et al. Triple-negative primary myelofibrosis: A Bone Marrow Pathology Group study. Mod Pathol. 2023;36(3):100016.
• Cantu MD, Kanagal-Shamanna R, Wang SA, et al. Clinicopathologic and molecular analysis of normal karyotype therapy-related and de novo acute myeloid leukemia: A multi-institutional study by the Bone Marrow Pathology Group. JCO Precis Oncol. 2023;7:e2200400.
• Frater JL, Hirsch-Ginsberg C, d'Onofrio G, et al. Arterial blood as an alternative specimen source for complete blood cell count: More human studies are needed. Int J Lab Hematol. 2023;45(3):e90-92.
• Konantz M, Williams M, Merkel T, et al. Increased TIM-3 and GAL-9 serum levels in patients with advanced systemic mastocytosis. J Allergy Clin Immunol. 2023;S0091-6749(23):00860-00866.
• Kumar J, Patel S, Chang A, et al. Smoking status in acute myeloid leukemia is associated with worse overall survival and independent of prior nonhematopoietic malignancies, cytogenetic abnormalities, and WHO category. Hum Pathol. 2023;135:45-53.
• Leguit RJ, Wang SA, George TI, et al. The international consensus classification of mastocytosis and related entities. Virchows Arch. 2023;482(1):99-112.
• Ohgami RS, Aung PP, Gru AA, et al. An analysis of the pathologic features of blastic plasmacytoid dendritic cell neoplasm based on a comprehensive literature database of cases. Arch Pathol Lab Med. 2023;147(7):837-846.
• Patel JL, Erba HP, Savona MR, et al. Genomic data heterogeneity across molecular diagnostic laboratories: A real-world Connect Myeloid Disease Registry perspective on variabilities in genomic assay methodology and reporting. J Mol Diagn. 2023;25(8):611-618.
• Ramia de Cap M, Wu LP, Hirt C, et al. Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group. Leuk Lymphoma. 2023;64(5):972-980.
• Shomali W, Colucci P, George TI, et al. Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group. Leukemia. 2023;37(5):981-987.
• Small C, Mukerjee S, Jangam D, et al. Profiling endogenous, environmental, and infectious disease mutational signatures in blastic plasmacytoid dendritic cell neoplasms. Int J Lab Hematol. 2023;10.1111/ijlh.14108.
• Tomlinson B, de Lima M, Cogle CR, et al. Transplantation referral patterns for patients with newly diagnosed higher-risk myelodysplastic syndromes and acute myeloid leukemia at academic and community sites in the Connect Myeloid Disease Registry: Potential barriers to care. Transplant Cell Ther. 2023;29(7):460.e1-e9.
• Valent P, Klion AD, Roufosse F, et al. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. Allergy. 2023;78(1):47-59.
• Bou Zerdan M, George TI, Bunting ST, et al. Recent advances in the treatment and supportive care of POEMS syndrome. J Clin Med. 2022;11(23):7011.
• Carter-Febres M, Stivers N, George TI, et al. Hemophagocytic lymphohistiocytosis associated with T cell acute lymphoblastic leukemia. Int J Lab Hematol. 2022;44(1):15-16.
• Genzen JR, Rychert J, George TI. Integrity of SARS-CoV-2 laboratory-developed tests. JAMA. 2022;328(5):478.
• Gerds AT, Gotlib J, Ali H, et al. Myeloproliferative neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(9):1033-1062.
• Gotlib J, Schwaab J, Shomali W, et al. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Disease (ECNM-AIM) response criteria in advanced systemic mastocytosis. J Allergy Clin Immunol Pract. 2022;10(8):2025-2038.e1.
• Hoermann G, Sotlar K, Jawhar M, et al. Standards of genetic testing in the diagnosis and prognostication of systemic mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. J Allergy Clin Immunol Pract. 2022;10(8):1953-1963.
• Kanagal-Shamanna R, Orazi A, Hasserjian RP, et al. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Mod Pathol. 2022;35(4):470-479.
• Pyatilova P, Akin C, Alvarez-Twose I, et al. Refined treatment response criteria for indolent systemic mastocytosis proposed by the ECNM-AIM consortium. J Allergy Clin Immunol Pract. 2022;10(8):2015-2024.
• Simpson SJ, Lim MY, George TI, et al. 36-year-old male with X-linked congenital sideroblastic anemia presenting as chronic microcytic anemia with iron overload. Int J Lab Hematol 2022;44(1):69-71.
• Sotlar K, George TI, Kluin P, et al. Standards of pathology in the diagnosis of systemic mastocytosis: recommendations of the EU-US Cooperative Group. J Allergy Clin Immunol Pract. 2022;10(8):1986-1998.e2.
• Valent P, Hartmann K, Bonadonna P, et al. Global classification of mast cell activation disorders: An ICD-10-CM-adjusted proposal of the ECNM-AIM consortium. J Allergy Clin Immunol Pract. 2022;10(8):1941-1950.
• Valent P, Hartmann K, Schwaab J, et al. Personalized management strategies in mast cell disorders: ECNM-AIM user’s guide for daily clinical practice. J Allergy Clin Immunol Pract. 2022;10(8): 1999-2012.e6.
• DeAngelo DJ, Radia DH, George TI, et al. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021;27(12):2183-2191.
• Carter Febres M, Abbott J, Cipriano SD, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS)-associated hemophagocytic lymphohistiocytosis (HLH), an important and underrecognized HLH mimic: A case report. Pediatr Blood Cancer. 2021;68(2):e28657.
• George TI, Bajel A. Diagnosis of rare subtypes of acute myeloid leukaemia and related neoplasms. Pathology. 2021;53(3):312-327.
• Gotlib J, Reiter A, Radia DH, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med. 2021;27(12):2192-2199.
• Gotlib J, George TI, Carter MC, et al. Proceedings from the inaugural American Initiative in Mast Cell Diesease (AIM) Investigator Conference. J Allergy Clin Immunol. 2021;147(6):2043-2052.
• Han SY, Mrózek K, Voutsinas J, et al. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Adv. 2021;5(10):2481-2489.
• Kelemen K, Saft L, Craig FE, et al. Eosinophilia/hypereosinophilia in the setting of reactive and idiopathic causes, well-defined myeloid or lymphoid leukemias, or germline disorders. Am J Clin Pathol. 2021;155(2):179-210.
• King RL, Tan B, Craig FE, et al. Reactive eosinophil proliferations in tissue and the lymphocytic variant of hypereosinophilic syndrome. Am J Clin Pathol. 2021;155(2):211-238.
• Lozano-Chinga M, Draper L, George TI, et al. Bone marrow necrosis in pediatric malignancies: 10-year retrospective review and review of literature. Pediatr Blood Cancer. 2021;68(3):e28806.
• Ok CY, Trowell KT, Parker KG, et al. Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/ MPL/ CALR) and SF3B1. Mod Pathol. 2021;34(1):20-31.
• Ozturk K, Cayci Z, Gotlib J, et al. Non-hematologic diagnosis of systemic mastocytosis: Collaboration of radiology and pathology. Blood Rev. 2021;45:100693.
• Patel JL, Abedi M, Cogle CR, et al. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. Int J Lab Hematol. 2021;43(3):426-432.
• Pozdnyakova O, Orazi A, Kelemen K, et al. Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2. Am J Clin Pathol. 2021;155(2):160-178.
• Rimsza L, Craig FE, Reichard KK, et al. Addressing the challenges of eosinophilia and mastocytosis. Am J Clin Pathol. 2021;155(2):156-159.
• Tzankov A, Duncavage E, Craig FE, et al. Mastocytosis. Am J Clin Pathol. 2021;155(2):239-266.
• Ustun C, Morgan EA, Ritz EM, et al. Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. Int J Lab Hematol. 2021;43(1):e19-e25.
• Weinberg OK, Chisholm KM, Ok CY, et al. Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Mod Pathol. 2021;34(7):1358-1366.
• Foucar K, Hsi ED, Wang SA, et al. Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study. Int J Lab Hematol. 2020;42(4), 418-422.
• George TI. Evolution of the International Journal of Laboratory Hematology. Int J Lab Hematol. 2020;42(Suppl 1):6-7.
• Gerds AT, Gotlib J, Bose P, et al. Myeloid/lymphoid neoplasms with eosinophilia and TK fusion genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(9);1248-1269.
• Hartmann K, Gotlib J, Akin C, et al. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. J Allergy Clin Immunol. 2020;146(2):356-366.e4.
• Hayward CPM, George TI, Van Cott EM, et al. Patient advocacy and its importance to laboratory medicine practice. Int J Lab Hematol. 2020;42(Suppl 1):21-22.
• Pollyea DA, George TI, Abedi M, et al. Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/ AML Disease Registry. EJHaem. 2020;1(1):58-68.
• Reiter A, George TI, Gotlib J. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis. Blood. 2020;135(16):1365-1376.
• Utz JL, Bell H, Wright WF, et al. "Soccer-ball" lymphocytosis. J Am Osteopath Assoc, 2020;120(4):286.
• Valent P, Akin C, Hartmann K, et al. Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. Theranostics. 2020;10(23):10743-10768.
• Bahr TM, Christensen RD, Agarwal AM, et al. The Neonatal Acute Bilirubin Encephalopathy Registry (NABER): background, aims, and protocol. Neonatology. 2019;115(3):242-246.
• Corean JLE, George TI, Patel JL, et al. Bone marrow findings in metastatic melanoma, including role of BRAF immunohistochemistry. Int J Lab Hematol. 2019;41(4):550-560.
• Gotlib J, Baird JH, George TI, et al. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. Blood Adv. 2019;3(15):2264-2271.
• Hoffmann JC, Lin CY, Bhattacharyya S, et al. Rosai-Dorfman disease of the breast with variable IgG4+ plasma cells: a diagnostic mimicker of other malignant and reactive entities. Am J Surg Pathol. 2019;43(12):1653-1660.
• Karner K, George TI, Patel JL. Current aspects of clonal hematopoiesis: implications for clinical diagnosis. Ann Lab Med. 2019;39(6):509­­­­-514.
• Li P, Shahmarvand N, Lynch D, et al. Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: borderline cases without anemia exist. Int J Lab Hematol. 2019;41(3):345-352.
• Bruegel M, George TI, Feng B, et al. Multicenter evaluation of the cobas m 511 integrated hematology analyzer. Int J Lab Hematol. 2018;40(6):672-682.
• Christensen RD, Agarwal AM, George TI, et al. Acute neonatal bilirubin encephalopathy in the state of Utah 2009-2018. Blood Cells Mol Dis. 2018;72:10-13.
• DeAngelo DJ, George TI, Linder A, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 2018;32(2):470-478.
• Goyal T, Thakral B, Wang SA, et al. T-cell large granular lymphocytic leukemia and coexisting B-cell lymphomas: a study from the bone marrow pathology group. Am J Clin Pathol. 2018;149(2):164-171.
• Hatch EW, Geeze MB, Martin C, et al. Variability of PD-L1 expression in mastocytosis. Blood Adv. 2018;2(3):189-199.
• Jennings SV, Slee VM, Zack RM, et al. Patient perceptions in mast cell disorders. Immunol Allergy Clin North Am. 2018;38(3):505-525.
• Margolskee E, Mikita G, Rea B, et al. A reevaluation of erythroid predominance in acute myeloid leukemia using the updated WHO 2016 criteria. Mod Pathol. 2018;31(6):873-880.
• Sumarriva Lezama L, Chisholm KM, Carneal E, et al. An analysis of blastic plasmacytoid dendritic cell neoplasm with translocations involving the MYC locus identifies t(6;8)(p21;q24) as a recurrent cytogenetic abnormality. Histopathology. 2018;73(5):767-776.
• Ustun C, Morgan E, Moodie EEM, et al. Core-binding factor acute myeloid leukemia with t(8; 21): risk factors and a novel scoring system (I-CBFit). Cancer Med. 2018;7(9):4447-4455.
• Gars E, Yousry SM, Babu D, et al. A replicable CD271+ mesenchymal stromal cell density score: bringing the dysfunctional myelodysplastic syndrome niche to the diagnostic laboratory. Leuk Lymphoma. 2017;58(7):1730-1732.
• George TI, Tworek JA, Thomas NE, et al. Evaluation of testing of acute leukemia samples: survey result from the College of American Pathologists. Arch Pathol Lab Med. 2017;141(8):1101-1106.
• Rogers HJ, Hsi ED, Tang G, et al. Most myeloid neoplasms with deletion of chromosome 16q are distinct from acute myeloid leukemia with inv(16)(p13.1q22): A Bone Marrow Pathology Group multicenter study. Am J Clin Pathol. 2017;147(4):411-419.
• Valent P, Akin C, Hartmann K, et al. Midostaurin: a magic bullet that blocks mast cell expansion and activation. Ann Oncol. 2017;28(10):2367-2376.
• Wang SA, Hasserjian RP, Tam W, et al. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica. 2017;102(8):1352-1360.